SCHEMBL6804084

SCHEMBL6804084

COc1c(O)ccc2c1O/C(=C\c1ccc(O)c(O)c1)C2=O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.70
TUBB4A P04350 1/20 0.65
TUBB P07437 1/20 0.65
TUBA3C P0DPH7 1/20 0.65
TUBA1B P68363 1/20 0.65
TUBA4A P68366 1/20 0.65
TUBB4B P68371 1/20 0.65
TUBB3 Q13509 1/20 0.65
TUBB2A Q13885 1/20 0.65
TUBB8 Q3ZCM7 1/20 0.65
TUBA3E Q6PEY2 1/20 0.65
TUBA1A Q71U36 1/20 0.65
TUBA1C Q9BQE3 1/20 0.65
TUBB6 Q9BUF5 1/20 0.65
TUBB2B Q9BVA1 1/20 0.65
TUBB1 Q9H4B7 1/20 0.65
STK17B O94768 5/20 0.61
AURKA O14965 3/20 0.61
GSK3B P49841 3/20 0.61
DAPK3 O43293 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29929543 1.00 APP (0.70) APPTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL6616173 1.00 APP (0.70) APPTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL6808883 0.91 TUBB4A (0.71) APPTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL6614015 0.91 TUBB4A (0.71) APPTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL6809135 0.89 TUBB4A (0.68) APPTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL6809134 0.89 TUBB4A (0.68) APPTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL6611437 0.82 APP (1.00) APPSTK17BAURKAGSK3BDAPK3
SCHEMBL30931489 0.82 APP (1.00) APPSTK17BAURKAGSK3BDAPK3
SCHEMBL6808382 0.82 APP (1.00) APPSTK17BAURKAGSK3BDAPK3
SCHEMBL6812730 0.80 APP (0.74) APPTUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 US claimed
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 US claimed
WO-2022182523-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2022-09-01 WO claimed
WO-2022182527-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2022-09-01 WO claimed
US-20040132807-A1 Aurones as telomerase inhibitors PHARMACIA ITALIA SPA (IT) 2004-07-08 US claimed
US-12569530-B2 Tannin-based antiproliferative pharmaceutical IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2026-03-10 US disclosed
US-12453799-B1 Bioadhesive for medical and dental applications IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY (SA) 2025-10-28 US disclosed
US-20250249063-A1 METHOD FOR TREATING ORAL CANCER IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2025-08-07 US disclosed
US-12318422-B2 Tannin-based antiproliferative pharmaceutical IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2025-06-03 US disclosed
US-20250161394-A1 Compositions Comprising Kavalactones NATURAL EXTRACTION SYS LLC (US) 2025-05-22 US disclosed
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 US disclosed
US-20240293492-A1 TANNIN-BASED ANTIPROLIFERATIVE PHARMACEUTICAL IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2024-09-05 US disclosed
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 US disclosed
WO-2022182527-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2022-09-01 WO disclosed
WO-2022182523-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2022-09-01 WO disclosed
US-11376570-B1 Method of forming copper oxide-on-copper nanomaterial catalyst mesh KING ABDULAZIZ UNIVERSITY (SA) 2022-07-05 US disclosed
EP-3986420-A1 NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES Mitopower LLC (US) 2022-04-27 EP disclosed
US-11311492-B1 Carbon nanomedicine with natural ligands KING ABDULAZIZ UNIVERSITY (SA) 2022-04-26 US disclosed
US-11234940-B1 Method for making a noble metal nanomedicine KING ABDULAZIZ UNIVERSITY (SA) 2022-02-01 US disclosed
US-20040132807-A1 Aurones as telomerase inhibitors PHARMACIA ITALIA SPA (IT) 2004-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES FABP2, FABP4, GUSB APP 1117/4885TUBB4A 1573/4885TUBB 1931/4885
US-20250249063-A1 METHOD FOR TREATING ORAL CANCER UGGT1, G6PD, UGT1A3 APP 2788/4885TUBB4A 192/4885TUBB 436/4885
US-20040132807-A1 Aurones as telomerase inhibitors TERT, TERF2, TERF2IP APP 3533/4885TUBB4A 575/4885TUBB 434/4885
US-20240293492-A1 TANNIN-BASED ANTIPROLIFERATIVE PHARMACEUTICAL UGGT1, G6PD, UGDH APP 3466/4885TUBB4A 323/4885TUBB 566/4885
US-12569530-B2 Tannin-based antiproliferative pharmaceutical SLC2A3, SLC2A1, SLC2A8 APP 3110/4885TUBB4A 505/4885TUBB 506/4885
US-12318422-B2 Tannin-based antiproliferative pharmaceutical UGGT1, G6PD, UGDH APP 3466/4885TUBB4A 323/4885TUBB 566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.